Welcome to our dedicated page for Rigel Pharmaceuticals SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a biotechnology company focused on hematologic disorders and cancer. Through these filings, investors can review Rigel’s official disclosures on its commercial portfolio, clinical pipeline and financial condition.
Rigel’s SEC submissions include current reports on Form 8-K that furnish press releases such as quarterly financial results and business updates. For example, recent 8-K filings reference press releases titled “Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update” and “Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update.” These documents outline total revenues, net product sales from TAVALISSE, GAVRETO and REZLIDHIA, contract revenues from collaborations, costs and expenses, net income, and cash, cash equivalents and short-term investments.
Filings also confirm key corporate details, including that Rigel Pharmaceuticals, Inc. is incorporated in Delaware and that its common stock, with a par value of $0.001 per share, is listed on The Nasdaq Stock Market LLC under the trading symbol RIGL. Investors can use these records to verify listing status, security information and the company’s description as a biotechnology business dedicated to therapies for hematologic disorders and cancer.
On Stock Titan’s SEC filings page, users can follow Rigel’s real-time submissions from the SEC’s EDGAR system, including Forms 8-K and, when available, annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy statements. AI-powered summaries help explain the key points of lengthy filings, highlighting items such as revenue composition, collaboration-related contract revenues, and updates on clinical programs like the Phase 1b study of R289 in lower-risk myelodysplastic syndrome.
In addition, the platform can surface insider transaction reports on Form 4 when filed, giving users a view into equity awards and other insider activity. By combining original SEC documents with AI-generated insights, this page is intended to make Rigel’s regulatory disclosures more accessible to both individual and professional investors.
Dean L. Schorno, EVP & Chief Financial Officer of Rigel Pharmaceuticals, was granted a performance-based employee stock option covering 7,394 shares of common stock with an exercise price of $22.49 (the closing Nasdaq price on the grant date). The option was originally granted on January 29, 2025 with an expiration date of January 29, 2035. Because the grant was subject to a performance-based vesting condition, it became reportable only after the company determined the performance metric was satisfied on September 15, 2025, at which point the option fully vested. Following the determination, the reporting shows 7,394 shares underlying the option beneficially owned, held directly. The Form 4 was signed by an attorney-in-fact and filed on September 17, 2025.
Dean L. Schorno, EVP & Chief Financial Officer of Rigel Pharmaceuticals, was granted a performance-based employee stock option covering 7,394 shares of common stock with an exercise price of $22.49 (the closing Nasdaq price on the grant date). The option was originally granted on January 29, 2025 with an expiration date of January 29, 2035. Because the grant was subject to a performance-based vesting condition, it became reportable only after the company determined the performance metric was satisfied on September 15, 2025, at which point the option fully vested. Following the determination, the reporting shows 7,394 shares underlying the option beneficially owned, held directly. The Form 4 was signed by an attorney-in-fact and filed on September 17, 2025.
David A. Santos, EVP and Chief Commercial Officer of Rigel Pharmaceuticals (RIGL) reported that a performance-based employee stock option covering 7,394 shares of common stock vested on September 15, 2025 after the required performance metric was determined to have been met. The option was originally granted on January 29, 2025 with an exercise price of $22.49 (the closing Nasdaq price on the grant date). The filing shows the option relates to 7,394 underlying shares and lists an expiration date of January 29, 2035. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact, Raymond Furey, on September 17, 2025.
David A. Santos, EVP and Chief Commercial Officer of Rigel Pharmaceuticals (RIGL) reported that a performance-based employee stock option covering 7,394 shares of common stock vested on September 15, 2025 after the required performance metric was determined to have been met. The option was originally granted on January 29, 2025 with an exercise price of $22.49 (the closing Nasdaq price on the grant date). The filing shows the option relates to 7,394 underlying shares and lists an expiration date of January 29, 2035. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact, Raymond Furey, on September 17, 2025.
RIGEL PHARMACEUTICALS, INC. (RIGL) reported a Section 16 filing showing a performance-based employee stock option became exercisable on 09/15/2025. The option covers 7,394 shares of common stock with an exercise price of $22.49, which equals the closing price on the grant date of 01/29/2025. The reporting person, Lisa Rojkjaer, identified as EVP and Chief Medical Officer, had the performance metric formally determined met on 09/15/2025, and the option fully vested that same day. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
RIGEL PHARMACEUTICALS, INC. (RIGL) reported a Section 16 filing showing a performance-based employee stock option became exercisable on 09/15/2025. The option covers 7,394 shares of common stock with an exercise price of $22.49, which equals the closing price on the grant date of 01/29/2025. The reporting person, Lisa Rojkjaer, identified as EVP and Chief Medical Officer, had the performance metric formally determined met on 09/15/2025, and the option fully vested that same day. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Raymond J. Furey, EVP, GC, CCO & Corporate Secretary of Rigel Pharmaceuticals, Inc. (RIGL), reported the vesting of a performance-based employee stock option covering 7,394 shares. The option was granted with an exercise price of $22.49 (the closing Nasdaq price on the grant date, 01/29/2025) and became fully vested on 09/15/2025 when the performance metric was determined to have been met. The Form 4 was filed on 09/17/2025.
This disclosure shows an insider equity award that converted from conditional to exercisable status, creating the right to acquire 7,394 common shares at $22.49 per share and increasing the reporting person’s beneficially owned options to 7,394 shares.
Raymond J. Furey, EVP, GC, CCO & Corporate Secretary of Rigel Pharmaceuticals, Inc. (RIGL), reported the vesting of a performance-based employee stock option covering 7,394 shares. The option was granted with an exercise price of $22.49 (the closing Nasdaq price on the grant date, 01/29/2025) and became fully vested on 09/15/2025 when the performance metric was determined to have been met. The Form 4 was filed on 09/17/2025.
This disclosure shows an insider equity award that converted from conditional to exercisable status, creating the right to acquire 7,394 common shares at $22.49 per share and increasing the reporting person’s beneficially owned options to 7,394 shares.
Raul R. Rodriguez, CEO and Director of Rigel Pharmaceuticals, Inc. (RIGL), reported vesting of a performance-based stock option covering 31,700 shares. The option was granted on January 29, 2025 with an exercise price of $22.49, equal to the closing Nasdaq price on the grant date. Because vesting was conditioned on a performance metric, the grant became reportable only after the metric was satisfied.
The performance condition was determined met and the option fully vested on September 15, 2025. Following the vesting event, Rodriguez directly holds the option to acquire 31,700 shares exercisable through January 29, 2035. The Form 4 was filed by one reporting person and signed via attorney-in-fact on September 17, 2025.
Raul R. Rodriguez, CEO and Director of Rigel Pharmaceuticals, Inc. (RIGL), reported vesting of a performance-based stock option covering 31,700 shares. The option was granted on January 29, 2025 with an exercise price of $22.49, equal to the closing Nasdaq price on the grant date. Because vesting was conditioned on a performance metric, the grant became reportable only after the metric was satisfied.
The performance condition was determined met and the option fully vested on September 15, 2025. Following the vesting event, Rodriguez directly holds the option to acquire 31,700 shares exercisable through January 29, 2035. The Form 4 was filed by one reporting person and signed via attorney-in-fact on September 17, 2025.
Armistice Capital, LLC and Steven Boyd filed a Schedule 13G/A reporting beneficial ownership of 1,600,000 shares of Rigel Pharmaceuticals, representing 8.92% of the outstanding common stock. The filing states these shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager and over which Armistice Capital and Mr. Boyd share voting and dispositive power.
The filing clarifies the Master Fund retains the economic right to proceeds or dividends while disclaiming direct beneficial ownership due to the investment management agreement. All reported share counts are based on 17,937,340 shares outstanding as of July 31, 2025, per the issuers SEC filing.
On 6 Aug 2025, Rigel Pharmaceuticals (RIGL) filed a routine Form S-8 to register 825,000 additional common shares for employee equity compensation: 125,000 shares under the Inducement Plan and 700,000 shares under the 2018 Equity Incentive Plan. The filing incorporates prior S-8s by reference and includes the usual legal opinions, consents and power-of-attorney exhibits; it contains no new earnings, balance-sheet data or corporate actions beyond the share registration. The statement ensures Rigel has sufficient shares available for future option and restricted-stock grants, supporting talent recruitment and retention. While the registration itself does not raise capital, any subsequent issuance of the shares will incrementally dilute existing shareholders.